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Abstract
Background: The CD4+ T-lymphocytes and their subtype CD4 + CD25highFoxP3+ regulatory T cells are receiving
growing interest as major regulators of atherogenesis. We sought to investigate 1) whether the CD4 + cell subsets
were expressed differently in dyslipidemic patients (Pts) and healthy subjects (HS) and 2) whether atorvastatin
treatment could be associated in-vivo and in-vitro with cell changes in expression and functional response.
Methods: CD4+ subsets frequency (CD4 + CD25highFoxP3+, CD4 + CD25-FoxP3+) and mRNA expression for FoxP3,
IL-10 and TGF-β were evaluated in 30 consecutive Pts at baseline and after a 3-month atorvastatin therapy, and in 17 HS.
Results: The % of CD4 + cells did not differ between HS and Pts. The % of CD4 + CD25highFoxP3+ was higher in Pts than
HS and did not change during treatment. The CD4 + CD25-FoxP3+ cells were similar between the two groups
and were lower in Pts at visit 2. Cytokine expression and FoxP3 did not differ in HS and Pts and no substantial
change was observed during treatment. At visit 1, CD4 + CD25highFoxP3+ cells were significantly correlated with both
total-cholesterol (r = 0.570, P = 0.0002), LDL-cholesterol (r = 0.715, P = 0.0001), Apolipoprotein B (r = 0.590, P = 0.0001).
In-vitro atorvastatin (up to 5 μM) failed to induce any significant modulation of cell functions.
Conclusion: CD4 + CD25highFoxP3+ regulatory cells seem to be over-stimulated in the early pre-clinical phase of
atherosclerosis and a relationship exists between their frequency and circulating lipids. A potential immuno-modulation
by statin treatment is not achieved through a normalization in peripheral CD4 + cell subsets.
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Background
Atherosclerosis is now considered an inflammatory
disease and it is well established that plaque initiation
and destabilization are strictly linked with mechanisms
involving both circulating and vascular immune cells
and mediators of inflammation [1–3].
Atherosclerotic lesions initiate with endothelial dam-
age and the proatherogenic potential of T cells is
crucial in the progression from fatty streaks to mature
plaques [4, 5]. Among the major classes of T lymphocytes,
the CD4+ cells are viewed as major regulators of athero-
genesis [1, 6]. Among the CD4+ subsets, specialized
lymphocytes play a key regulatory role in the suppression
of immune responses against self as well as foreign anti-
gens, thus being pivotal for the suppression of detrimental
Th1 immune responses [7].
In animal models the functional interplay between
regulatory T cells and CD4+ effectors T lymphocytes
may be critical in the control of atherosclerotic plaque
development [8–11]. Regulatory T cells are now viewed
as the master modulators of the immune system
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possessing the immunosuppressive capacity to prevent
unfavorable immune responses and maintain tolerance
to self-antigens and therefore as a potential therapeutic
target [12]. Moreover, it is of great interest to understand
whether pharmacological treatments can modulate the T
regulatory control system.
Beyond the cholesterol-reducing effect, statins may
interfere with inflammatory mechanisms associated with
atherosclerosis and functional tissue responses, and
recent evidence points to an interaction between these
drugs and both the innate and adaptive immune cell
function [13–19].
We sought to investigate in dyslipidemic subjects bearing
an increased risk for vascular events whether the CD4+ cell
subsets, including specific T cell subsets known to be
involved in the immune-response regulation, such as
T cells characterized as CD4 + CD25highFoxP3+, were
differently expressed compared to controls. As a sec-
ondary endpoint, we evaluated whether atorvastatin ex
vivo and in vitro treatment could be associated with




We enrolled 30 consecutive dyslipidemic patients (Pts)
evaluated at our Lipid outpatient Clinic who showed a
“moderate risk” for vascular events according to the
NCEP - Adult Treatment Panel III (ATPIII) guidelines [20].
Subjects were included in the study if a lipid-lowering
pharmacological treatment with statin was clinically in-
dicated and they did not assume any pharmacological
treatment. Ongoing clinical infection and/or the pres-
ence of infections in the previous three months were
considered as exclusion criteria. The Pts were studied
after 6 weeks of life-style modification including dietary
treatment (qualitative counseling) and recommendations
for mild physical activity. Pts were studied at the day of in-
stitution of atorvastatin (10–20 mg/od) therapy (visit 1)
and 3 months later (visit 2). We also enrolled a control
group of healthy subjects (HS), showing a low cardiovas-
cular risk according to ATPIII. Blood samplings were
obtained between 8.00 and 9.00 A.M., after a fasting
night. Laboratory examinations included total cholesterol
(Tot-c), low density lipoprotein cholesterol (LDL-c), high
density lipoprotein cholesterol (HDL-c), Tryglicerides
(TG), Apolipoprotein B (ApoB) and apolipoprotein A
(ApoA), fasting glycemia, serum C-reactive protein
(CRP). Our study complies with the Declaration of
Helsinki; the “Circolo and Macchi Foundation Hospital”
Ethics Committee has approved the research protocol
and written informed consent has been obtained from
the subjects.
Isolation of peripheral blood mononuclear cells (PBMCs)
PBMC were isolated as previously described [13]. Purity
and viability of cells were assessed by means of flow cyto-
metric assay and a typical PBMCs preparations contained
about 80 % lymphocytes and 16 % monocytes and cell via-
bility was always >99 %. One samples of 2 × 106 cells were
immediately assayed for the study of the frequency of the
major CD4+ T cell subsets.
Flow cytometry analysis of CD4+ subsets frequency
The frequency of circulating total CD4+ T cells as well
of CD4+ T cell subsets was evaluated by a two-color flow
cytometric analysis. Moreover, Forkhead box P3 (FoxP3)
intracellular staining was evaluated to study the frequency
of CD4 +CD25highFoxP3+ T cells, according to the proto-
col recommended by eBioscience (San Diego, CA, USA).
Acquisition was performed on a FACSCanto II flow
cytometer (BD Bioscience, Milan, Italy) and data were
analyzed with BD FACSDiva software (version 6.1.3;
BD Bioscience). Total CD4+ T lymphocytes were identified
and gated on the side scatter vs CD4-FITC dot plot and
regulatory T cells frequency was expressed as percentage
(%) of CD25high FoxP3+ cells among CD4+ T cells.
Purification of CD4+, CD4 + CD25+ and CD4 + CD25- T
lymphocytes for real time PCR assays
CD4+ were obtained from whole blood by means of
immunomagnetic cell sorting using the CD4+ Positive
Isolation (Dynal Biotech, Invitrogen). CD4 + CD25+ and
CD4 + CD25- subsets were obtained by means of immu-
nomagnetic cell sorting using CD4+ Negative Isolation
and subsequently using the anti-CD25 monoclonal anti-
bodies contained in the CD4 + CD25+ T Cell isolation
Kit (Miltenyi Biotec). For all the cell subsets, after
immunomagnetic cell sorting, the purity and the viability
were assessed by flow cytometry and were always >96–
99 %; samples were subsequently analyzed by measuring
the expression of the mRNA for FoxP3, which is a tran-
scription factor expressed in high amount on CD4 +
CD25+ T lymphocytes.
RNA isolation and real-time PCR analysis
Total mRNA was extracted from 1 × 106 cells by Manual
PerfectPureTM RNA Cell & Tissue (5PRIME, GmbH).
RNA was reverse transcribed using the high-capacity
cDNA Archive Kit (Applied Biosystems, Foster City, USA)
and real time PCR were performed as previously described
[21]. Finally, raw data were analyzed by the ABI prism
SDS software (Applied Biosystems) and primers (Ct1)
mRNA expression data were obtained from Ct values,
normalized to 18 s RNA (Ct2) (housekeeping) content and
finally expressed as 2-Δct for each gene.
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Cell viability, CFSE staining and cell proliferation assay
Cell viability tests on PBMC and CD4+ were performed
by means of flow cytometry and propidium iodide (PI)
staining. Acquisition was performed on a BD FACS-
Canto II flow cytometer. Cells were identified on the
basis of the forward-scatter (FSC) and side-scatter (SSC)
properties, and a minimum of 15.000 cells from each
sample was collected in the gate. Finally, cell viability
was assessed by calculating the percentage (%) of cells
negative at PI staining with respect to total cells in-
cluded in the gate. For cell proliferation, PBMC, CD4+,
and CD4 + CD25- were resuspended in RPMI 1640 with-
out fetal bovine serum (107cells/ml) and incubated with
5,6-carboxy fluorescein diacetate succinimidyl ester
(CFSE; 1 μM; 5 min, 37 °C). Cells were then resuspended
in RPMI supplemented with 10 % of FBS and washed
two times, cells were resuspended in culture medium and
cultured. Phytohaemagglutinin (PHA; 10 μg/mL)-induced
cell proliferation was assessed for PBMC, CD4+ and
for coculture of CD4 +CD25+ and CD4 +CD25- (ratio:
CD4 + CD25+ /CD4 + CD25- = 1:1). The PHA was se-
lected as stimulus for both PBMC and T reg according to
our previous results [22].
Then, cells were incubated for 5 days in a 37 °C in 5 %
of CO2. At the end of culture, cells were centrifuged
(300 g, 10 min) washed one time in PBS 1X and then
prepared for the cytofluorimetric analysis. Cell proliferation
was measured by using 488 nm excitation and emission
filters appropriate for fluorescein. A minimum of 20,000
events were analyzed and data were expressed as % of
CFSE low cells (% of proliferation).
Ability of atorvastatin to influence in vitro FoxP3 and
cytokine expression
Atorvastatin (concentration range: 0.001–10 μM) was
added on PBMC or CD4 + 1 h before PHA (10 μg/ml)
and incubated for 24 h (for cytokine production) or 48 h
(for FoxP3 expression).
At the end of cell culture, cells were harvested and
stored (−80 °C) for the subsequent real time assay of
cytokine mRNA expression, while PBMC and CD4+ were
analyzed with flow cytofluorimetric technique for the
evaluation of FoxP3 on CD4+ specific subsets.
Enzyme-linked immunosorbent assay (ELISA)
Cytokine production was measured in cell culture su-
pernatants by using commercialized enzyme-linked
immunosorbent assay (ELISA, Amersham, UK).
Statistical analysis
Our study was designed as a pilot study. We also have
not found any previous study to calculate sample size
and statistical power. Data are presented as mean and
standard deviation (SD) or median and 25–75th percentile
range (IQR) if continuous and as counts and percent if
categorical. Comparisons between dependent measures
were performed with the Wilcoxon signed-rank test. The
Bonferroni correction was applied for post hoc compari-
sons. Comparisons between independent measures were
performed with the Mann–Whitney U test. The relation-
ships between both the T cell subsets and T cell subsets
potential changes during treatment, and both baseline
levels and changes occurring during the follow-up in lipid
parameters (Tot-c, LDL-c, ApoB) were investigated using
univariate analysis by Spearman Rank correlation and then
by linear regression analysis. Calculations were performed
using commercial software (Stata 11, Stata Corp, College
Station, TX, USA). A two-sided P, 0.05 was retained for
statistical significance.
Results
Effect of 3-month treatment with atorvastatin on cell
subsets of dyslipidemic Pts and comparison with HS
Clinical and laboratory parameters in Pts and HS
Mean age and gender distribution were similar in Pts and
HS (49 ± 9 vs 45 ± 8 years, P = 0.21; 80 % males vs 65 %),
as well as body mass index (BMI) and waist circumference
(WC) [(BMI 26.8 ± 4 vs 23.7 ± 3.4 kg/m2 (P = 0.07); WC
97.4 ± 10.6 vs 87.3 ± 10.7 cm (P = 0.052)]. 19 Pts and 6 HS
were habitual smokers (7 ± 5 cigarette/day) and no subject
changed the smoking habitus during the study. Laboratory
parameters of both Pts and HS are shown in Table 1.
Values measured in Pts at visit 1 were significantly differ-
ent with respect to values measured in HS fot TotC,
LDLc, ApoB and TG. In Pts, the Tot-c, LDL-c, ApoB and
TG were significantly reduced after atorvastatin treatment
(visit 2).
T cells subsets in Pts and HS
The % of CD4+ cells did not differ between HS [35.9
(34.2–47.6)] and untreated Pts at visit 1 [43.5 (34.5–49.0)]
(P = 0.372). Comparing Pts at the two visit times, no dif-
ference was found between the % of CD4+ [(visit 2: 41.8
(36.2–49.1)] (P = 0.294). The % of CD4+ cells obtained
from Pts at visit 2 was similar to the % of CD4+ cells of
HS (P = 0.315). A significant difference was observed in
the % of CD4 +CD25highFoxP3+ (P = 0.03) (Fig. 1, panel
a). CD4 + CD25-FoxP3+ were similar between the two
groups of subjects (P = 0.509) (Fig. 1, panel b). No differ-
ences were observed between Pts at the two visit times
with regards to CD4 + CD25highFoxP3+ (P = 0.826) and at
visit 2 the values remained higher when compared to HS
(P = 0.03). The % of CD4 + CD25-FoxP3+ cells measured
at visit 2 was significantly lower than the values measured
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at visit 1 (P = 0.014) and these values did not differ from
those measured in HS (P = 0.322) (Fig. 1).
mRNA expression for FoxP3, IL-10 and TGF-β in CD4 +
CD25+ and CD4 + CD25- cells of Pts and HS
As shown in Table 2, mRNA expression for IL-10, TGF-β
and FoxP3 did not differ in CD4 +CD25+ and CD4 +
CD25- cells of HS and untreated Pts. No change was
observed between Pts values during the study (vist 2 vs
visit 1) for IL-10 and TGF-β in CD4 +CD25+ and CD4 +
CD25- cells. FoxP3 mRNA expression was significantly
reduced in CD4 + CD25- cells (P = 0.019).
Relationships between T cells subsets and both clinical and
laboratory parameters
The % of CD4+ cells was not related with LDL-c, HDL-c,
TG, ApoB and ApoA whereas tended to be associated
(R 0.298, P = 0.073) with Tot-c. CD4 +CD25highFoxP3+
cells were significantly correlated with both Tot-c, LDL-c,
ApoB (Fig. 2). We didn’t found significant correlation be-
tween HDL-c and CD4 + CD25highFoxP3+ cells (R = 0.172;
P = 0.303).
After dividing the sample into healthy and hypercholes-
terolemic subjects, these correlations remained statistically
significant only in Pts (data not shown). The associations
remained significant when adjusting for smoking habits.
Table 1 Laboratory parameters before institution of atorvastatin treatment (visit 1) and after 3 months (visit 2)
HS (n = 17) Pts (n = 30)
P* vs Pts P**
Visit 1 Visit 2 Visit 1 Visit 2 Visit 2 vs 1
Tot-c (mg/dL) 198.0 (188.5–221.5) <0.0001 0.036 269.0 (226.0–318.0) 166.0 (141.5–204.5) <0.0001
LDL-c (mg/dL) 115.0 (107.0–147.5) 0.003 n.s. 168.0 (119.3–263.5) 135.0 (94.0–196.5) 0.0013
HDL-c (mg/dL) 53.0 (44.0–67.5) n.s. n.s. 49.5 (42.8–56.3) 47.0 (39.5–54.5) n.s.
TG (mg/dL) 132.0 (102.5–163.5) 0.002 0.0004 181.5 (137.7–220.6) 87.0 (61.2–111.9) <0.0001
ApoA (mg/dL) 144.0 (121.5–161.0) n.s. n.s. 126.0 (114.3–139.5) 130.0 (112.0–143.5) n.s.
ApoB (mg/dL) 98.0 (85.0–108.5) <0.0001 0.038 139.0 (120.0–155.0) 80.0 (64.0–.98.0) <0.0001
hs-CRP (mg/L) 1.50 (0.60–2.70) n.s. n.s. 0.90 (0.45–2.20) 1.1 (0.7–2.4) n.s.
Glucose (mg/dL) 96 (89–97) n.s. n.s. 93.5 (89.75–102) 96 (89.75–100) n.s.
Values are expressed as median and 25–75th percentile
n.s. not significant
* = Mann Whitney test; ** = Wilcoxon signed rank test
Fig. 1 Percent of FoxP3 expression in CD4 + CD25high (panel a) and CD4 + CD25- (panel b) subsets analyzed by means of flow cytofluorimetric
assay in venous blood from HS (empty circles) and Pts at the two visit times (empty squares: visit 1; filled squares: visit 2). Data are expressed as
median and 25 and 75th percentile. § = P 0.03 visit 1 vs HS (Mann–Whitney test); * = P 0.014 visit 2 vs visit 1 (Wilcoxon matched pairs test);
# = P 0.03 visit 2 vs HS (Mann–Whitney test)
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At a univariate analysis we didn’t see any correlation
between CD4 + CD25highFoxP3+ cells and age, body mass
index, systolic and diastolic blood pressure, waist circum-
ference, fasting plasma glucose, creatinine levels. So we
didn’t include these variables in the regression analysis
model.
At a univariate analysis we found a significant correlation
only between Apo B and waist circumference (R = 0.412;
P = 0.014) . Adding waist circumference to the regression
analysis model we confirmed the association between Apo
B and CD4 + CD25highFoxP3+ cells.
Changes in lipid profile after atorvastatin treatment
were not associated with changes in CD4 + CD25high-
FoxP3+ cells measured between the two visits (data not
shown). No association was found between CD4 +CD25-
FoxP3+ cells and the lipid profile. No relationship was ob-
served between mRNA levels (FoxP3, IL-10 and TGF-β)
and clinical (age, blood pressure, smoking habitus) and la-
boratory parameters (lipid parameters, CRP levels) both in
CD4 +CD25+ and CD4 + CD25- cells (data not shown).
In vitro study: effect of stimulation with atorvastatin on
cell subsets
Effect of treatment with atorvastatin on PBMCs and CD4+
T lymphocytes
We tested the ability of atorvastatin to modulate cell
viability (24 h – 5 die), proliferation (5 die) and
cytokine production (24 h; IFNγ/IL-4) on PBMCs
and CD4+ cells (see Table 3). Atorvastatin up to
1 μM, did not affect any parameter investigated
while higher concentrations significantly influenced
all the parameters investigated with the only excep-
tion of resting cell viability in PBMCs and IL-4
mRNA expression both in PBMCs and CD4+ T lym-
phocytes (Table 3).
Effect of atorvastatin on frequency of CD4 + CD25high and
on FoxP3 expression
Treatment of PBMCs with atorvastatin (concentration
range: 0.1–10 μM) for 24 h did not affect the frequency
of CD4+, CD4 + CD25+, CD4 + CD25-, CD4 + CD25high-
FoxP3+ and CD4 + CD25-FoxP3+ (data not shown); in
addition in the same conditions, no differences were ob-
served in % of FoxP3+ expression in the same cell subsets
when cells were treated with atorvastatin for 24 or 48 h
(data not shown). As shown in Table 4, incubation for
48 h with atorvastatin did not affect PHA-induced FoxP3
expression up to 5 μM, wheres incubation with 10 μM
atorvastin induced a significant reduction of FoxP3
expression on CD4+ (P < 0.05 vs PHA) and on CD4 +
CD25+ (P < 0.05 vs PHA). Atorvastatin did not influence
FoxP3 expression on CD4 + CD25- (P > 0.05 vs PHA).
Effect of atorvastatin on coculture of CD4 + CD25- and
CD4 + CD25+ cells
Co-culture of CD4 + CD25- cells and CD4 + CD25+ cells
(1:1) induced a decrease in PHA-induced CD4 + CD25-
cells proliferation (CD4 + CD25-: 63.3 ± 21.1, co-culture:
25.5 ± 22.3; n = 5; P = 0.004); incubation with atorvastatin
before PHA (concentration range: 0.001–1 μM) did not
affect the CD4 + CD25+ cells inhibitory effect (P > 0.05
for all the concentrations tested).
Discussion
The complex regulatory network of T cells comprises a
number of T cell subpopulations with distinct phenotypes
and distinct mechanisms of action as CD4 + CD25 +
FoxP3+ T cells, possibly influencing the atherosclerotic
processes through inhibition of immune responses [23].
Only a few studies investigated in patients the relation-
ship between regulatory T cells and atherosclerosis, and
Table 2 mRNA expression for IL-10, TGF-β and FoxP3 before atorvastatin (visit 1) and after 3 months (visit 2)
HS (n = 17) Pts (n = 30)
P* vs Pts P**
Visit 1 Visit 2 1 2 Visit 2 vs 1
CD4 + CD25+ cells
IL-10 1.46 (0.202–4.747) 0.455 0.058 1.65 (0.3355–4.100) 1.52 (0.134–3.350) 0.173
TGFβ 18.070 (11.510–37.770) 0.111 0.178 39.850 (14.850–62.850) 32.300 (15.200–56.000) 0.185
FoxP3 252.600 (72.520–389.700) 0.811 0.858 138.000 (56.800–581.00) 274.000 (59.900–534.000) 0.417
CD4 + CD25- cells
IL-10 0.018 (0.008–0.321) 0.263 0.171 0.328 (0.105–0.447) 0.101 (0.008–0.230) 0.203
TGFβ 0.851 (0.317–2.055) 0.097 0.428 1.780 (0.716–4.575) 1.640 (0.297–13.700) 1.000
FoxP3 0.545 (0.208–0.968) 0.627 0.425 0.574 (0.155–3.090) 0.273 (0.133–0.887) 0.019
Values are expressed as median and 25–75th percentile range
* = Mann Whitney test; ** = Wilcoxon signed rank test
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very few authors reported longitudinal results on potential
changes of these cells frequency and/or function after
pharmacological cardiovascular treatments in vascular
diseases.
In our study we report that dyslipidemic, otherwise
healthy, patients at increased cardiovascular risk show
a mild, but significant, increase in CD4 + CD25high-
FoxP3+ cells and a similar expression of the other
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Fig. 2 Correlations between CD4 + CD25high FoxP3+ cells and Tot-c (panel a), LDL-c (panel b) and ApoB (panel c) in untreated Pts and HS. The
non parametric Spearman R correlation coefficient was computed together with its p-value
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CD4+ subsets studied when compared to control
subjects.
A significant reduction of regulatory CD4+ cells or
FoxP3+ cells, together with altered functional activities,
was previously reported in patients with acute coronary
syndrome or in vulnerable patients who had undergo at
least two myocardial infarctions in medical history com-
pared with both normal subjects and patients with stable
angina [24–28]. Besides the setting of acute myocardial
infarction, peripheral Th17/Treg imbalance has been
reported in patients with acute atherosclerotic cerebral
infarction [29]. In a prospective cohort, CD4 + FoxP3+
cells and not CD4 +CD25 + FoxP3+ cells were independ-
ent predictors of acute myocardial infarction whereas no
relation was found with stroke [30].
In patients with vascular lesions, unstable carotid
plaques patients showed lower levels of regulatory T
cells, regulatory T-related cytokines (IL-10 and TGF-β1),
and FoxP3 mRNA [31].
On the other hand, previous observations in chronic
stable atherosclerosis showed that the atherosclerotic bur-
den is not related to T regulatory cells expression. Indeed
in patients submitted to carotid echography evaluation,
the intima-media thickness was not related to regulatory
T cell levels in a large patient population and no differ-
ences in regulatory T cell levels were observed comparing
rapid versus slow intima-media thickness progressors [32].
Moreover, an absence in regulatory T cells level alteration
was confirmed in chronic stable angina patients [32].
In our dyslipidemic patients who did not show ouvert
vascular diseases and therefore in a pre-clinical stage of
atherosclerosis, we found a hightly significant correlation
between CD4 + CD25highFoxP3+ cells and both Tot-c,
LDL-c and ApoB. Hypercholesterolemia was found to
induce an accumulation of regulatory T lymphocytes in
the atherosclerotic aorta and spleens in mice, but the
regulatory T cells content is not maintained over time
under sustained hypercholesterolemic conditions [33].
Possibly the characteristics of the patient population of
the present study may account for our results.
Adaptive immune responses may change in the
progression of the atherosclerotic process and increased
levels of CD4CD25highFoxP3+ cells may represent an early
response to initial changes associated with atherosclerosis.
Table 3 In vitro effect of stimulation with atorvastatin (0.001–10 μM) on PBMC and CD4+
PBMC
Atorvastatin (μM)
Control 0.001 0.1 1 5 10
Resting cell viability (% of PI negative)a 100 ± 2.11 101.41 ± 0.64 96.89 ± 3.63 102.82 ± 1.28 = 101.43 ± 2.19
PHA-induced cell viabilityb 100.00 ± 27.59 106.10 ± 9.81 107.40 ± 14.65 107.50 ± 23.48 50.76 ± 42.44* 33.72 ± 20.61**
PHA-induced cell proliferationb 100.00 ± 26.24 98.61 ± 15.79 96.83 ± 35.19 83.47 ± 25.37 62.26 ± 22.45 33.82 ± 22.84**
PHA-induced IL-4 mRNA expressiona 100.00 ± 38.99 = = 103.90 ± 35.17 98.97 ± 40.82 83.34 ± 37.06
PHA-induced IFN- mRNA expressiona 100.00 ± 48.40 = = 102.50 ± 32.99 56.97 ± 32.36 17.03 ± 10.88*
CD4+
Atorvastatin (μM)
PHA (10 μg/ml) 0.001 0.1 1 5 10
Cell viabilitya 100 ± 10.66 98.12 ± 2.92 103.60 ± 7.14 84.88 ± 20.64 53.04 ± 17.73* 34.69 ± 17.28**
Cell proliferationb 100.30 ± 34.75 91.92 ± 13.94 105.10 ± 18.60 109.60 ± 42.90 37.38 ± 4.37* 13.03 ± 10.32**
IL-4 mRNA expressiona 100.00 ± 25.99 = = 133.20 ± 64.78 98.97 ± 33.77 62.11 ± 6.19
IFN- mRNA expressiona 100.00 ± 39.62 = = 127.20 ± 35.17 123.70 ± 66.18 54.17 ± 27.68
Cells were cultured for 1 (a) or 5 (b) days as appropriate. Values are expressed as percentage of resting values (presented in table as control) or of values obtained
after stimulation with PHA (10 ng/ml) and finally expressed as mean ± SD of at least 4–6 separate experiments; P values were assessed by ANOVA followed by
Dunnett comparison
* = P < 0.05; ** = and P < 0.0001 vs respective control
Table 4 In vitro effect of atorvastatin on FoxP3 expression in CD4+ subsets obtained from healthy subjects
Atorvastatin (μM)
PHA 1 5 10
CD4 + FoxP3+ (%) 78.17 ± 9.03 80.30 ± 4.35 72.33 ± 9.77 60.79 ± 9.39*
CD4 + CD25 + FoxP3+ (%) 78.81 ± 8.23 80.46 ± 1.32 74.17 ± 8.48 64.28 ± 7.63*
CD4 + CD25-FoxP3+ (%) 19.56 ± 12.64 10.20 ± 3.82 17.46 ± 12.07 11.80 ± 9.65
Values are expressed as mean ± SD; P values were assessed by ANOVA followed by Dunnett comparison; * = P < 0.05 vs respective control
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It has been shown that inflammed enviroments may modu-
late FoxP3-driven epigenetic modifications [34]. Systemic
inflammation as expressed by serum CRP, was similar in
our groups of healthy subjects and dyslipidemic patients,
pointing to very early modifications occurring in our pa-
tients in the “atherosclerosis continuum” from functional
disturbances to ouvert diseases.
Moreover, in this study we showed that a 3-month
atorvastatin treatment in dyslipidemic patients is not
associated with changes in expression of CD4+ cells
and/or in functional properties of both CD4+ subset
and CD4 + CD25highFoxP3+ T cells.
The clinical significance of specific newly identified
subsets of T cells is still under investigation and cell
types such as CD4 + CD25-FoxP3+ are now receiving
increasing attention. Although some authors found that
these cells phenotypically, and to a certain extent also
functionally, resemble conventional T regulatory cells,
others point to a dysfunctional nature of the suppressive
effect of these cell type [35, 36]. In the present study
the MFI of CD4 + CD25-FoxP3+ measured during ator-
vastatin treatment was significantly lower than values
measured at baseline, though this value did not differ
from values measured in HS. These observations are
derived by evaluation of the phenotype and therefore
we are not allowed to have clues on functional parameters
of these cells and their potential changes during treatment.
Only a few previous studies have investigated the potential
influence of statin treatment on regulatory T cells. In
normocholesterolemic healthy subjects a short-term
treatment with low doses of lovastatin or atorvastatin
was associated to increased CD4 + FoxP3+ cells. Con-
versely to our results, the authors found also a significant
correlation between CD4 + FoxP3+ cells and HDL-c levels
[37]. When CD4 + CD25+ T cells were investigated in
the setting of acute myocardial infarction, the inhibitory
activity of CD4 +CD25+ regulatory T cells was found to
be modified with atorvastatin treatment [28, 38]. A previ-
ous retrospective study reported that simvastatin (20 mg;
n = 7) and pravastatin (10-40 mg; n = 5) treatment were
associated with increased CD4 + CD25high in hypercholes-
terolemic subject [39]. In PBMCs of patients with acute
coronary syndrome, in-vitro simvastatin 10 μM was able
to increase the percentage of CD4 + CD25 + FoxP3+ regu-
latory T cells to total CD4+ cells [40]. However it is known
that statin levels during clinical treatment do not reach
levels comparable to the higher concentrations used for
in-vitro experiments. In our in-vitro study, treatment of
PBMC and CD4+ susbsets with atorvastatin failed to
induce any significant modulation of cell functions in
the concentration-range comparable to clinical treat-
ment, while interestingly 10 μM significantly reduced
cell viability and affected cell functions. In particular, in
the co-colture stimulated for proliferation, the expected
inhibitory effect of CD4 + CD25+ cells on CD4 + CD25-
was not reversed by pretreatment with atorvastatin, there-
fore atorvastatin does not influence these cells physiological
functioning. Taken together, both our data obtained during
chronic statin administration in a prospective study and in-
vitro observations point to the absence of significant effects
of atorvastatin therapy on CD4+ subsets in dyslipidemic
patient except for the CD4 +CD25-FoxP3+ cell type.
Although we did not observe relevant changes in the
circulating T cell subpopulation studied, it cannot be
ruled out the possibility of different local concentration
of cells in inflammed vascular tissues or specific differ-
entiations induced by local mediators or that potential
conflicting results could be obtained using other statins.
Moreover, the follow-up time and/or the atorvastatin
dose used in our study could be inadequate to observe
potential changes/redistribution of the immune cells
subsets.
Conclusions
Our results show that the immune system cell types in-
volved in regulatory mechanisms may be over stimulated
in the early pre-clinical phase of atherosclerosis and
that a relationship exists between CD4 + CD25high-
FoxP3+ frequency and circulating lipids. A potential
immuno-modulation by statins is not achieved in a
short term follow-up period through a normalization in
peripheral CD4+ cell subsets. Moreover, in-vitro ator-
vastatin does not seem to affect the CD4+ subtypes
function.
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